TSHA (Taysha) Company Cash Volume

Taysha Corp - graphic logo of issuer TSHA

Taysha Gene Therapies develops cutting-edge treatments for CNS pathologies by delivering genes to the brain using viral vectors. Development relies on automated molecular genome screening via robotic stations. The production cycle is outsourced to external CMO partners. The cash balance history on this chart demonstrates liquidity, where the 0.43 level indicates the status of the business's financial stability parameter.

Company Cash Balance: Taysha Gene Therapies Inc (TSHA) for 07/04/2022 - 11/21/2026

Taysha Gene Therapies, Inc. - analytical breakdowns and key metrics (TSHA)

Basic company analysis:Taysha Gene Therapies Inc
Signature product of tayshagtx.com

For investors, the balance between liquidity and capital efficiency is critical, particularly in the capital-intensive field of gene therapy for rare CNS pathologies. By analyzing free cash flow, we assess the ability of Taysha Gene Therapies (TSHA) to fund its AAV developments and clinical partnerships without external borrowing, where growing reserves signal either preparation for expansion or stagnation of the operating cycle.

Competitors of Taysha Gene Therapies (TSHA)

Company Cash Volume TEM|QGEN - Company Cash Reserve|ionispharma.com - Company Cash on Hand|Company Cash Balance RGEN|Avidity Corp - Company Cash Volume|CRISPR Therapeutics Corp - Company Total Cash Amount|GeneDx Holdings (WGS) - Company Cash Funds|Ultragenyx Pharmaceutical (RARE) - Company Cash Volume|Company Cash on Hand BEAM|Sarepta (SRPT) - Company Liquid Assets|Company Cash Funds Twist Bioscience Corp (TWST)|10x - Company Cash and Cash Equivalents|Company Cash Volume NTLA (intelliatx.com)|Company Total Cash Amount STOK (stoketherapeutics.com)|BioLife Solutions Inc - Company Cash Volume|WVE (Wave Life Sciences Ltd) - Company Cash and Cash Equivalents|Maze Therapeutics Corp (MAZE) - Company Cash Funds|Company Cash and Cash Equivalents SION|PRME (Prime Medicine Inc) - Company Cash Volume|QURE - Company Cash Position|Company Cash on Hand MGTX (MeiraGTx Holdings plc)|REGENXBIO (RGNX) - Company Cash Position|Company Cash Volume SLDB (Solid Biosciences Inc.)|Company Cash Balance OCGN|PacBio Corp - Company Cash Volume|Benitec Biopharma Inc. (BNTC) - Company Cash on Hand|DSGN: Company Cash Volume|Company Cash and Cash Equivalents RCKT|Company Cash on Hand FDMT|Company Cash and Cash Equivalents LXEO (Lexeo Therapeutics)|Company Cash Volume KRRO|Editas Medicine, Inc. - Company Cash and Cash Equivalents|Company Cash Funds Silence Therapeutics Inc. SLN|Company Cash Volume ProQR Therapeutics N.V. PRQR|CDXS: Company Cash on Hand|Company Cash Position Sangamo (SGMO)|NAUT (Nautilus Bio) - Company Cash on Hand|MGX - Company Liquid Assets|DTIL (Precision BioSciences Inc.) - Company Cash Volume|generationbio.com (GBIO) - Company Liquid Assets|Company Cash Funds Boundless Bio Inc (BOLD)|Company Cash Volume Exicure Inc. (XCUR)|Company Cash Funds imunon.com IMNN|Company Cash Volume Phio Pharmaceuticals PHIO|Mustang Bio Inc - Company Cash Volume|Company Cash Reserve transcodetherapeutics.com|BNGO: Company Cash Volume|Company Cash and Cash Equivalents APDN|BLUE (bluebirdbio.com) - Company Cash Volume|Company Cash Reserve ImmunoPrecise Antibodies IPA|Company Cash on Hand OMGA (omegatherapeutics.com)|Company Cash Volume Singular Genomics Systems, Inc. (OMIC)|Company Cash Volume RGLS (Regulus Therapeutics, Inc.)|Company Cash Volume Syros SYRS|Telesis Bio, Inc. - Company Cash Volume|TRACON Pharmaceuticals (TCON) - Company Cash on Hand|UBX: Company Cash Volume